Pregabalin Capsule
Product Images NDC 71335-9699

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-9699). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713359699)

This is a description of Pregabalin Capsules, a medication distributed by Bryant Ranch Prepack, Inc. Each capsule contains 200mg Pregabalin, and caution should be taken to keep medication away from children. It should be stored at room temperature, and dispensed in child-resistant containers. Further medication guide information is available through the provided link. Information on the manufacturer, ScieGen Pharmaceuticals, Inc. is also included.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

The text contains data on the percentage of patients improved and the percentage improvement in pain from baseline, but it is difficult to interpret due to the formation and symbols present.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

This is a description of the improvement observed in patients receiving Pregabalin 160mg for 3 days. It shows the percentage of patients improved in pain from baseline, with values of 100%, 2%, and 10% reported. There is also a table with some numerical values that is not clearly related to the main information.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

The text is not available.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

FDA Label Image

Figure 5 (Pregabalin Fig05)

This appears to be a table showing the dosages and results of a study comparing the pain relief effectiveness of Fregabalin, Pregataiin, and a placebo. The table shows the dosage frequency for each treatment, and a chart displaying how many patients saw improvement with each treatment. It also includes a percentage improvement chart in pain for each treatment.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

FDA Label Image

Figure 7 (Pregabalin Fig07)

FDA Label Image

Figure 9 (Pregabalin Fig08)

The text displays a chart showing the percentage of patients who improved while taking Pregabalin at different daily doses and a placebo. The percentage of improvement is measured in pain reduction from baseline. The chart shows that Pregabalin at 300mg and 450mg daily doses improved the condition in a higher percentage of patients compared to those who took a placebo. No further information is available.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

FDA Label Image

Figure 11 (Pregabalin Fig10)

FDA Label Image

Figure 12 (Pregabalin Fig11)

The text seems to be a chart or a table that shows the percent improvement of subjects in a study. The study is likely comparing the efficacy of two treatments, Pregabalin and Placebo, over 16 weeks. The percent improvement ranges from 100 to 280 and is measured at various points from 210 to 270. However, without more context, it is not possible to provide a conclusive description of the data.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

This is a formula used to calculate creatinine clearance (CLCT), which is an estimate of kidney function. It involves multiplying 140 minus the patient's age (in years) by their weight (in kilograms), then multiplying that result by 0.85 for female patients. The final step is to multiply that result by the patient's serum creatinine level (in milligrams per deciliter), divided by 72.*

FDA Label Image

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.